

Application No. 10/643,404
Amendment dated June 22, 2007
Reply to Office Action dated March 22, 2007

2

Docket No.: 59753(48185)

AMENDMENTS TO THE CLAIMSRECEIVED
CENTRAL FAX CENTER

JUN 22 2007

This listing of claims will replace all prior versions and listings of claims in the application.

1. (Previously presented) A method for therapy of arterial wall injury which is caused by coronary angioplasty or coronary-artery bypass graft (CABG), which comprises a step of administering 3-methyl-1-phenyl-2-pyrazolin-5-one or the physiologically acceptable salt thereof, or the hydrate or solvate thereof in a therapeutically effective amount to mammals including humans.
2. (Cancelled)
3. (Cancelled)
4. (Previously presented) The method according to claim 1 wherein the arterial wall injury is restenosis or neointimal formation after coronary angioplasty or coronary-artery bypass graft (CABG).
5. (Currently amended) The method according to claim 1, claim 4, or claim 6 [(or 4)] wherein the coronary angioplasty is percutaneous transluminal coronary angioplasty (PCTA) or percutaneous coronary intervention (PCI).
6. (New) A method for therapy of neointimal formation, restenosis, or reocclusion of vascular lumens, which is caused by coronary angioplasty or coronary-artery bypass graft (CABG), which comprises a step of administering 3-methyl-1-phenyl-2-pyrazolin-5-one or the physiologically acceptable salt thereof, or the hydrate or solvate thereof in a therapeutically effective amount to mammals including humans.